Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement in Patients <60 Years of Age.


Journal

Cardiovascular revascularization medicine : including molecular interventions
ISSN: 1878-0938
Titre abrégé: Cardiovasc Revasc Med
Pays: United States
ID NLM: 101238551

Informations de publication

Date de publication:
10 2022
Historique:
received: 07 07 2021
revised: 06 04 2022
accepted: 09 05 2022
pubmed: 8 6 2022
medline: 28 9 2022
entrez: 7 6 2022
Statut: ppublish

Résumé

Transcatheter aortic valve replacement (TAVR) is an alternative therapeutic modality to surgical aortic valve replacement (SAVR) in patients with severe aortic stenosis (AS). In the current analysis, we compare the characteristics and outcomes of AVR procedures in patients <60 years of age. We queried the Nationwide Readmissions Database for all AVR hospitalizations in patients 18-59 years of age between January 2012 and December 2017. We performed a propensity score matching analysis (1:1) and compared baseline characteristics, procedural complications, and outcomes between TAVR and SAVR patients. A total of 72,356 hospitalizations for AVR were identified in patients <60 years of age. Compared to their SAVR counterparts, TAVR patients were older (52.5 ± 7.6) vs. 48.8 ± 9.6, p < 0.001), more likely to be women (37.9% vs. 28.0%, p < 0.001), and have history of prior radiation (8.3% vs. 0.7%, p < 0.001). After propensity score matching, TAVR patients had lower procedural complications, but a similar mortality rate compared to SAVR patients (2.9% vs. 3.0%, p = 0.77). TAVR was associated with a shorter length of hospital stay [4 [2-9] vs. 6 [5-11], p < 0.001), but no significant difference in the 30-day readmission rate was noted (16.2% vs. 16.8%, p-value = 0.49). Our study demonstrates favorable short-term outcomes in younger patients undergoing TAVR, which improved over time. Further investigation of long-term outcomes in TAVR performed younger patients is warranted to draw a comprehensive picture of TAVR safety and efficacy in low-risk patients.

Sections du résumé

BACKGROUND
Transcatheter aortic valve replacement (TAVR) is an alternative therapeutic modality to surgical aortic valve replacement (SAVR) in patients with severe aortic stenosis (AS). In the current analysis, we compare the characteristics and outcomes of AVR procedures in patients <60 years of age.
METHODS
We queried the Nationwide Readmissions Database for all AVR hospitalizations in patients 18-59 years of age between January 2012 and December 2017. We performed a propensity score matching analysis (1:1) and compared baseline characteristics, procedural complications, and outcomes between TAVR and SAVR patients.
RESULTS
A total of 72,356 hospitalizations for AVR were identified in patients <60 years of age. Compared to their SAVR counterparts, TAVR patients were older (52.5 ± 7.6) vs. 48.8 ± 9.6, p < 0.001), more likely to be women (37.9% vs. 28.0%, p < 0.001), and have history of prior radiation (8.3% vs. 0.7%, p < 0.001). After propensity score matching, TAVR patients had lower procedural complications, but a similar mortality rate compared to SAVR patients (2.9% vs. 3.0%, p = 0.77). TAVR was associated with a shorter length of hospital stay [4 [2-9] vs. 6 [5-11], p < 0.001), but no significant difference in the 30-day readmission rate was noted (16.2% vs. 16.8%, p-value = 0.49).
CONCLUSION
Our study demonstrates favorable short-term outcomes in younger patients undergoing TAVR, which improved over time. Further investigation of long-term outcomes in TAVR performed younger patients is warranted to draw a comprehensive picture of TAVR safety and efficacy in low-risk patients.

Identifiants

pubmed: 35672240
pii: S1553-8389(22)00238-X
doi: 10.1016/j.carrev.2022.05.008
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

7-12

Informations de copyright

Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors report no conflict of interest in relation to this submission.

Auteurs

Mohamed M Gad (MM)

Cleveland Clinic Foundation, Cleveland, OH, United States of America.

Islam Y Elgendy (IY)

Division of Cardiology, Weill Cornell Medicine-Qatar, Doha, Qatar.

Anas M Saad (AM)

Cleveland Clinic Foundation, Cleveland, OH, United States of America.

Ahmed N Mahmoud (AN)

Case Western Reserve University School of Medicine and Harrington Heart and Vascular Institute, Cleveland, OH, United States of America.

Toshiaki Isogai (T)

Cleveland Clinic Foundation, Cleveland, OH, United States of America.

Johnny Chahine (J)

University of Minnesota, Minneapolis, MN, United States of America.

Amer N Kadri (AN)

Beaumont Health, Dearborn, MI, United States of America.

Ravi Ghanta (R)

Division of Cardiovascular Medicine, Baylor School of Medicine, Houston, TX, United States of America.

Ernesto Jimenez (E)

Division of Cardiovascular Medicine, Baylor School of Medicine, Houston, TX, United States of America.

Samir R Kapadia (SR)

Cleveland Clinic Foundation, Cleveland, OH, United States of America.

Hani Jneid (H)

Division of Cardiovascular Medicine, Baylor School of Medicine, Houston, TX, United States of America. Electronic address: jneid@bcm.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH